Clinical Trials, Research and Development
February 4, 2021
Via: BioSpaceAgenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary results from its Phase 1 trial of iNKT […]
July 11, 2024
July 11, 2024
July 19, 2024